Bulletin: Pathway to Approval: United States FDA Approves First Biosimilar Drug
On March 6th, 2015, the United States Food and Drug Administration (FDA) approved the first biosimilar drug, Zarxio (filgrastim-sndz). A biosimilar is a successor to a biologic medicine which has lost patent exclusivity. Zarxio, like its reference product Neupogen, is indicated for the treatment of neutropenia, the abnormally low count of neutrophils, a type of white blood cell that helps fight off infections. The approval of this biosimilar by the U.S. FDA has important implications for healthcare system stakeholders, especially payers and patients. Payers are acutely aware of high cost specialty medications and the increasing impact they have on overall drug spend. As specialty drug utilization increases rapidly each year, the approval of this first biosimilar has been a highly anticipated event.
US Script Announces New Chief Medical Officer
US Script is pleased to announce the appointment of Ross Hoffman, M.D. to the role of Chief Medical Officer. Dr. Hoffman is a board certified cardiologist with 25 years healthcare experience including clinical, diagnostic and invasive cardiology. In addition to serving cardiovascular patients, Dr. Hoffman develops programs and products for health care software and IT companies, commercial and government payers, hospital systems and medical device companies.
US Script’s Director of PharmaHealth Analytics, Tim Emert, to present Understanding Pharmacy Spend and Managing Costs
US Script’s Director of PharmaHealth Analytics, Tim Emert, will be presenting Understanding Pharmacy Spend and Managing Costs during the Administrative & Financial Considerations Track May 22nd at 10am at Institute for International Research USA 21st Annual Medicaid Managed Care Congress in Baltimore. This original presentation will examine the impact of pharmacy spend in overall healthcare plans and the potential implications of healthcare reform and Medicaid expansion. Visit us at the conference in booth #11.
US Script Parent Company, Centene Corporation, Rises in 2013 FORTUNE 500 Ranking
FORTUNE Magazine's recently released annual ranking of America's largest corporations by revenue placed Centene Corporation at #303 for 2013. Centene, which moved up 150 places from last year's ranking, experienced strong growth in 2012, with total revenues of $8.7 billion, up from $5.3 billion in 2011.
"Centene's position this year illustrates our expanding presence as a national leader in healthcare services," said Centene Chairman and Chief Executive Officer Michael F. Neidorff. "We have continued to advance higher in FORTUNE's annual ranking for the past several years. By offering a diverse array of solutions to improve the health of communities, one person at a time, we will continue to be well positioned to meet our growth objectives over the next several years."
In 2012, Centene was awarded nine new health plan contracts and grew its revenue by 62% over the previous year. US Script provides innovative pharmacy benefit solutions for 15 of its 20 health plans.
Centene Corporation Completes Acquisition Of Specialty Pharmacy Leader AcariaHealth
We are pleased to announce that, effective April 1st, US Script’s parent company, Centene Corporation completed the acquisition of Specialty Therapeutic Care Holdings, Inc. (d/b/a AcariaHealth). AcariaHealth, headquartered in Orlando, Florida, is one of the nation's largest independent comprehensive specialty pharmacy companies, operating seven Specialty Pharmacy locations across the US.
The addition of AcariaHealth to the Centene family enhances US Script’s comprehensive pharmacy solution for complex disease conditions, including Hepatitis C, Hemophilia, Multiple Sclerosis, Rheumatoid Arthritis and Oncology. This acquisition allows US Script to offer an integrated specialty solution, enhancing the suite of services that we can offer to new and existing clients.
For more information about the AcariaHealth acquisition, please contact your Account Manager or Elisa McNamara, Director of Marketing and Strategy at email@example.com.
US Script Named Sole Recipient of United Way Circle of Excellence Award
US Script is honored to be the recipient of the United Way of Fresno County’s Circle of Excellence Award for 2012-13. This award is granted to one organization each year that exemplifies communal spirit by addressing unique issues that directly affect the well-being of those in the Fresno community.
For more information on the LIVE UNITED campaign and to view US Script President and CEO, Pete Clagett discuss how US Script Lives United, CLICK HERE.
Toll Free: (800) 460-8988
TTY: (866) 492-9674
For press releases or any media related communications, please contact us at via email at firstname.lastname@example.org.
If you are requesting story information, please include the information below in your email:
- Publication or Broadcast Affiliation
- Nature of Story/Topic
- Contact Information